Tryp Therapeutics Reaches Milestone on Psilocybin Drug Manufacturing Program

La Jolla, California–(Newsfile Corp. – February 16, 2021) – Tryp Therapeutics (CSE: TRYP) (“Tryp” or the…

Tryp Therapeutics Appoints Dr. Joel Castellanos as Clinical Advisor

La Jolla, California–(Newsfile Corp. – February 11, 2021) – Tryp Therapeutics (CSE: TRYP) (“Tryp” or the…

Tryp Therapeutics Plans Phase 2a Eating Disorder Clinical Trial with Dr. Jennifer Miller

La Jolla, California–(Newsfile Corp. – February 8, 2021) – Tryp Therapeutics (CSE: TRYP) (“Tryp”), a leading…

Tryp Therapeutics Announces Appointment of Greg McKee as Executive Chairman

La Jolla, California–(Newsfile Corp. – February 3, 2021) – Tryp Therapeutics (CSE: TRYP) (“Tryp”), a leading…

Tryp Therapeutics Appoints Dr. Robin Carhart-Harris to Scientific Advisory Board

La Jolla, California–(Newsfile Corp. – February 2, 2021) – Tryp Therapeutics, a clinical-stage pharmaceutical company developing…

Tryp Therapeutics Strengthens Board of Directors with Appointment of Gregory M. McKee

La Jolla, California–(Newsfile Corp. – January 14, 2021) – Tryp Therapeutics Inc. (CSE: TRYP) (“Tryp” or…

Tryp Therapeutics Appoints Dr. William K. Schmidt to Its Scientific Advisory Board

La Jolla, California–(Newsfile Corp. – January 7, 2021) –  Tryp Therapeutics (CSE: TRYP) (“Tryp” or the…

Tryp Therapeutics Begins Trading on the Canadian Securities Exchange

La Jolla, California–(Newsfile Corp. – December 18, 2020) – Tryp Therapeutics Inc. (CSE: TRYP) (“Tryp” or the “Company“)…